Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation

Hepatobiliary and Pancreatic Diseases International

Volumn 6, Issue 4, 2007, Pages 376-378

  Yang, Yong Jiu ^a   Li, Li Xin ^a   He, Qiang ^a   Fan, Hua ^a   Jin, Zhong Kui ^a   Lang, Ren ^a   Kou, Jian Tao ^a   Li, Peng ^a   Xie, De Hong ^a   Chen, Da Zhi ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Kidney failure; Liver transplantation; Sirolimus

Indexed keywords

ANTILIPEMIC AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITROGEN; PREDNISONE; RAPAMYCIN; TACROLIMUS; UREA;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; GENERAL CONDITION IMPROVEMENT; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LEUKOPENIA; LIVER DISEASE; LIVER FUNCTION; LIVER TRANSPLANTATION; MALE; PATIENT MONITORING; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL;

ADULT; CALCINEURIN; CREATININE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; SIROLIMUS; TACROLIMUS;

EID: 34548079047     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Mukherjee T, Shah BV. Sirolimus: a new immunosuppressant. J Assoc Physicians India 2005;53:885-890.
2. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35(3 Suppl):7S-14S.
3. Salerno A, Bonanno CT, Caccamo N, Cigna D, Dominici R, Ferro C, et al. The effect of cyclosporin A, FK506 and rapamycin on the murine contact sensitivity reaction. Clin Exp Immunol 1998;112:112-119.
4. Forgacs B, Merhav HJ, Lappin J, Mieles L. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Transplant Proc 2005;37:1912-1914.
5. Kniepeiss D, Iberer F, Schaffellner S, Jakoby E, Duller D, Tscheliessnigg KH. Nonnephrotoxic immunosuppression in patients after liver transplantation. Int Immunopharmacol 2005;5:133-136.
6. Fujii N, Ikeda K, Koyama M, Aoyama K, Masunari T, Kondo E, et al. Calcineurin inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation. Int J Hematol 2006;83:459-461.
7. Höcker B, Feneberg R, Köpf S, Weber LT, Waldherr R, Wühl E, et al. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity. Pediatr Transplant 2006;10: 593-601.
8. Cohen AJ, Stegall MD, Rosen CB, Wiesner RH, Leung N, Kremers WK, et al. Chronic renal dysfunction late after liver transplantation. Liver Transpl 2002;8:916-921.
9. Lebrón Gallardo M, Herrera Gutierrez ME, Seller Pérez G, Curiel Balsera E, Fernández Ortega JF, Quesada García G. Risk factors for renal dysfunction in the postoperative course of liver transplant. Liver Transpl 2004;10:1379-1385.
10. Morard I, Mentha G, Spahr L, Majno P, Hadengue A, Huber O, et al. Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels. Clin Transplant 2006;20:96-101.
11. Orlando G, Baiocchi L, Cardillo A, Iaria G, De Liguori Carino N, De Luca L, et al. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl 2007;13: 46-54.
12. Voisard R, Gecgüner L, Baur R, Herter T, Hombach V. Antiproliferative profile of sirolimus and mycophenolate mofetil: impact of the SI/MPL ratio. Int J Cardiol 2005;102: 435-442.
13. Berry V, Magill A, Yost M, Janosky J, Sindhi R. Individualizing combination of two antiproliferative immunosuppressants with pharmacodynamic modeling of stimulated lymphocyte responses. Cytometry A 2006;69:95-103.
14. Wali RK, Mohanlal V, Ramos E, Blahut S, Drachenberg C, Papadimitriou J, et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007;7:1572-1583.
15. Barten MJ, Streit F, Boeger M, Dhein S, Tarnok A, Shipkova M, et al. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. Transplantation 2004;77:1154-1162.
16. Zaghla H, Selby RR, Chan LS, Kahn JA, Donovan JA, Jabbour N, et al. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation. Aliment Pharmacol Ther 2006;23:513-520.
17. Marks AR. Rapamycin: signaling in vascular smooth muscle. Transplant Proc 2003;35(3 Suppl):231S-233S.
18. Andrés V, Castro C, Campistol JM. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients. Nephrol Dial Transplant 2006;21 Suppl 3:iii14-17.
19. Saikali JA, Truong LD, Suki WN. Sirolimus may promote thrombotic microangiopathy. Am J Transplant 2003;3: 229-230.
20. Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2003;9:463-468.
21. Langer RM, Kahan BD. Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients. Transplantation 2003;76:318-323.